08:02 AM EDT, 10/16/2026 (MT Newswires) -- The European Medicines Agency's human medicines committee recommended approval of France-based Orphelia Pharma's Kizfizo for newly diagnosed glioblastoma multiforme in adults and recurrent or progressing malignant glioma in adults and children aged one and older. The recommendation is backed by satisfactory results in studies and its bioequivalence to Merck & Co.'s (6MK.F) Temodal, according to a Friday note. The drug remains subject to final approval from the European Commission.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.